// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Long term outcome following mitral valve repair or replacement: the impact of concomitant atrial fibrillation treatment and sinus rhythm restoration

L. Di Bacco - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Effect of sacubitril/valsartan on plasma biomarkers that reflect extracellular matrix regulatory mechanisms and collagen synthesis in patients with heart failure and reduced ejection fraction

J. Rouleau - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Sacubitril/valsartan

Clinical application of computed tomography aortic valve calcium scoring

A. Evangelista - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely Ill medical patients: insights from the APEX trial

R.D. Hull - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

betrixaban

Mutations in ILK (integrin linked kinase) are associated with human arrhythmogenic cardiomyopathy and decreased survival in zebrafish

A. Brodehl - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care

W.F. Peacock - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Heparin

ICD use in arrhythmogenic right ventricular cardiomyopathy: prophylactic vs secondary indication

M.J. Gardner - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Lowering the neutrophil to lymphocyte ratio by the BET inhibitor, apabetalone: potential implications for cardiovascular events in high risk patients

S. Nicholls - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

RVX-208

Bnip3 Displaces Uncoupling Protein3 (UCP3) from cytochrome C oxidase of respiration chain complex IV promoting maladaptive autophagy and necrotic cell death in doxorubicin cardiotoxicity

L.A. Kirshenbaum - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Doxorubicin

Factors influencing ambulance use in patients with suspected acute coronary syndromes: a population-based geographic information system study

N. Sepehrvand - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Neurodevelopmental disorders in patients with RYR2-associated catecholaminergic polymorphic ventricular tachycardia

S.R.W. Chen - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Adherence to cardiac surgical waitlist guidelines is a poor predictor of cardiac surgery waitlist mortality

J. Senaratne - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The spectrum of cardiovascular disease after early stage breast cancer: a population-based cohort study

H. Abdel-Qadir - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A meta-analysis of INR targets for mechanical heart valves: we need new evidence

J. Willingstorfer - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The effect of apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial

D.S. Shishikura - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

RVX-208

Cardiopulmonary, vascular and biomarker responses to acute hypoxic stress following cardiac transplantation

M. Sanz - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

ILS-969

Differences in clinical measures and outcomes in South Asians (SA) vs Caucasians (CA) attending a cardiac rehabilitation program (CRP)

G. Nanayakkara - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Is relying on ST depression to help predict coronary artery disease after an out-of-hospital cardiac arrest harming patients?

M.E. Farkouh - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Lifestyle risk factors for non-valvular atrial fibrillation

C.A. Buzea - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Hydroxyzine

Predictors of cognitive decline after cardiac surgery: an evaluation of the CABG off or on pump revascularization study (CORONARY) cohort

J. Spence - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved